Letermovir Use in French HCT Recipients: A National Claims Database Study

France's national health claims database was used to study letermovir prophylaxis for cytomegalovirus in allogeneic hematopoietic cell transplantation recipients. The dataset covers patients who received the drug between March 2020 and December 2021, with follow-up data extracted for analysis. Sophie Ducastelle-Lepretre authored this retrospective cohort study, which was posted on figshare.

Use Cases

• Analyze real-world prophylaxis duration based on the reported mean and median course lengths.
• Study patient demographics and treatment patterns based on the cohort of 1,649 included patients.
• Investigate the association between initial letermovir exposure and subsequent need for a second course.
• Model clinical event rates based on the follow-up of patients with complete letermovir courses.

Strengths

• Based on a national health data system (SNDS), likely providing population-level coverage for France.
• Includes data on 1,649 patients with letermovir prophylaxis, offering a substantial cohort size.
• Reports specific, detailed metrics such as a mean prophylaxis duration of 152.0 days (SD 96.4).
• Follows patients for at least six months post-initiation, providing medium-term outcome data.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect temporal bias inherent to the specific study period (2020-2021).

Provenance

Source

French National Health Data System (SNDS)

Collection Method

Non-interventional retrospective cohort study based on claims data.

Time Range

March 2020 to December 2021

Freshness

Last updated 2026-05-18 05:43:08; freshness should be verified.

Geography

France